Tharimmune’s $540M Crypto Gamble: Biotech Giant Bets Big on Canton Coin Treasury

Biotech meets blockchain in a stunning $540 million corporate treasury pivot.

The Crypto Conversion

Tharimmune just dropped half a billion dollars into Canton Coin reserves—transforming their balance sheet into a digital asset powerhouse overnight. This isn't just dipping toes in crypto waters; it's a full-scale corporate treasury revolution.

Market Impact

The move sends shockwaves through both biotech and crypto sectors. Traditional finance analysts are scratching their heads while digital asset proponents cheer the institutional validation. Another case of legacy money finally catching up to where smart capital has been parking for years.

Because nothing says 'confidence in traditional markets' like betting half a billion on experimental digital assets while your core business develops medical treatments.

TLDR

• Tharimmune raised $540 million in private funding to build a crypto treasury strategy focused on Canton Coin, the native token of the Canton Network.
• The private placement was led by DRW and Liberty City Ventures, with participation from ARK Invest, Polychain Capital, Kraken, and other institutional investors at $3.075 per share.
• Tharimmune plans to use the funds to purchase Canton Coin tokens, become a Super Validator on the network, and operate additional nodes while maintaining its biotech business.
• The Canton Network is a permissioned enterprise blockchain backed by Goldman Sachs, HSBC, BNP Paribas, Deutsche Bank, and other major financial institutions.
• Tharimmune stock jumped over 120% initially following the Monday announcement before settling around $3.39, up nearly 15% for the day.

Tharimmune raised $540 million in a private placement to launch a digital asset treasury strategy centered on Canton Coin. The Nasdaq-listed biotech company announced the funding round on Monday.

Tharimmune makes $540M bet on Canton Coin in crypto treasury push The biotech company's pivot into digital assets marks one of the largest treasury financings to date, underscoring growing institutional demand for tokenized finance. pic.twitter.com/v08EmmnYnj

— Oya San (@IamOyaSan) November 4, 2025

The deal was priced at $3.075 per share. Leading investors include DRW and Liberty City Ventures.

ARK Invest, Broadridge, Kraken, and Polychain Capital also participated in the round. Other institutional investors joined as well.

Tharimmune, Inc., THAR

The Canton Foundation took part in the investment. This marks the foundation’s first investment in a publicly traded company.

Tharimmune will use the capital to purchase Canton Coin tokens. The company also plans to maintain its existing biotech operations, which focus on developing therapeutic candidates for inflammation and immunology disorders.

Validator Role and Network Participation

The company intends to become a Super Validator on the Canton Network. This role involves operating additional nodes to earn token rewards.

Running validator nodes will help strengthen network performance. Tharimmune plans to build applications on the Canton Network as part of its expanded role.

Canton Coin serves as the native token of the Canton Network. The network is a permissioned enterprise blockchain built for institutional use.

The blockchain enables interoperability between financial applications and tokenized assets. Digital Asset Holdings developed the Canton Network infrastructure.

Major Financial Institutions Back Network

Goldman Sachs, HSBC, and BNP Paribas back the Canton Network. Deutsche Bank, Paxos, and Cboe are also among its supporters.

The DTCC uses the network for tokenization and settlement infrastructure. Digital Asset raised $135 million earlier this year in a Goldman-backed funding round.

DRW and Tradeweb led that round. The capital went toward expanding institutional use cases for the network.

Trading firm DRW Holdings and Liberty City Ventures will contribute part of their investment directly in Canton Coins. Canton Coin is not yet listed on crypto exchanges.

The private placement is expected to close around November 6. The deal represents one of the largest digital asset financings to date.

Tharimmune stock reacted sharply to the announcement. Shares surged more than 120% to nearly $6.70 following the news.

The stock quickly pulled back from those highs. By Monday afternoon, shares were trading around $3.39.

This represented a gain of nearly 15% for the day. The stock closed Monday up 8.4% on Nasdaq.

Tokenized assets now total more than $34.6 billion according to RWA.xyz data. This includes $18.4 billion in private credit and $8.7 billion in US Treasury debt.

Commodities account for $3 billion of the total. Traditional finance companies continue moving operations to blockchain infrastructure.